{"entity":{"id":"paper-baisley-doris-one-dose-hpv-tanzania-lgh-2022","kind":"paper","name":"DoRIS: one dose of HPV vaccine in Tanzanian girls compared with historical cohorts","aka":[],"tldr":"In the DoRIS trial in Mwanza, antibody levels two years after a single dose of HPV vaccine in girls aged 9 to 14 were not inferior to those in cohorts where one dose had protected for up to 11 years, supporting a one-dose schedule.","summary":"Published as \"Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial\". DoRIS (NCT02834637) enrolled 930 girls from 54 government schools in Mwanza in 2017 and 2018 and randomised them to one, two or three doses of the 2-valent or 9-valent vaccine.","asOf":"2026-11-11","links":[{"label":"Lancet Glob Health 2022","url":"https://doi.org/10.1016/s2214-109x(22)00306-0"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/36113532/"}],"tags":[],"related":["hpv-vaccine"],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"The Lancet Global Health","year":2022,"doi":"10.1016/s2214-109x(22)00306-0","pmid":"36113532","authors":"Baisley K, Kemp TJ, Kreimer AR, et al.","paperType":"rct","findings":["930 girls were enrolled and 155 assigned to each of six schedules.","At 24 months, HPV16 antibody levels after one dose of 2-valent vaccine were 22.9 IU/mL against 17.7 in the Costa Rica trial (ratio 1.30), and after one dose of 9-valent vaccine 13.7 against 6.7 in the IARC India trial (ratio 2.05).","Non-inferiority was met for both vaccines and for both HPV16 and HPV18."],"whatItMeans":"Tanzanian girls in this trial gave part of the evidence that one dose of HPV vaccine may be enough, the schedule Tanzania itself adopted in 2024.","caveats":["Antibody levels are a bridge to protection, not a measure of prevented cancers.","Girls with HIV were not eligible."],"participants":930},"route":"/key-papers/paper-baisley-doris-one-dose-hpv-tanzania-lgh-2022/","neighbours":{"technology":[{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/"}],"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"institution":[{"id":"tanzania-ministry-of-health","kind":"institution","name":"Ministry of Health, Tanzania","route":"/institutions/tanzania-ministry-of-health/"}]}}